U.S. Telemedicine Advertising Rules: Avoid GLP-1 Ad Blocks
Use this U.S. telemedicine ad checklist to manage FTC claims, compounded GLP-1 promotion, licensure, privacy, and Google and LegitScript reviews.
U.S. Telemedicine Advertising Rules: Avoid GLP-1 Ad Blocks
U.S. telemedicine advertising rules start with one standard: your ads must be truthful and backed by evidence, under FTC substantiation rules. Compounded drugs can never be sold as FDA-approved or equivalent to brand drugs. Licensure, privacy law, and platform verification apply on top. Below you get a checklist and a launch playbook.
TL;DR:
- Support every health claim with well conducted human clinical studies; disclose preliminary evidence clearly, and place payment or free service disclosures beside endorsements.
- The FDA warned 30 telehealth companies about false marketing; never describe compounded drugs as approved by the FDA or equivalent to brand drugs.
- Treatment authority follows the patient’s location, so target only states where clinicians are licensed and name each clinician’s authorized states on the landing page.
- Keep health information out of URLs and forms, confirm business associate agreements with vendors, and map each campaign’s data flow from click to customer records.
- Prepare license, business, and clinical workflow documents for Google and LegitScript, and remove drug access language while explaining the clinician visit on landing pages.
Table of Contents
- What should you check before any telehealth ad runs?
- What does the FTC expect from your health and outcome claims?
- How do you avoid FDA trouble with compounded drug promotion?
- How do you handle testimonials, reviews, and patient consent?
- Where can you advertise versus where can you treat?
- What privacy and HIPAA rules touch your ads?
- Why do Google Ads and LegitScript block telehealth campaigns?
- How do you launch a compliant campaign, step by step?
- Why compliance is a growth strategy, not a tax
- How can KLYR Media help your telehealth marketing stay compliant?
- FAQ
- Sources
What should you check before any telehealth ad runs?
Run this list past legal review before a single dollar of spend goes out:
- Every health claim has written support on file.
- No ad promises a prescription or guaranteed access to a drug.
- Testimonials and influencer posts disclose any material connection.
- Targeting excludes states where your clinicians are not licensed.
- Landing pages carry no protected health information in URLs or form fields.
- Review privacy and security safeguards for vendors that handle patient data.
- Compounded products are never called “FDA-approved” or “the same as” a brand drug.
- Google and LegitScript documents are ready before you submit.
- Emergency-care and telemedicine-limitation disclaimers appear on the page.
- Subscription and billing terms are visible before checkout.
File claim evidence in the creative folder, disclosures with the ad assets, and clinician license records with your credentialing files.
Pro Tip: Keep a compliance log for every ad and landing page: version, date, reviewer, and approved claims. When a regulator or platform asks, you answer in minutes.
What does the FTC expect from your health and outcome claims?
The FTC expects health claims to rest on competent and reliable scientific evidence, which generally means well-conducted human clinical studies. If you say a program helps patients lose weight or lower blood pressure, you need that proof before the ad goes live, not after a complaint arrives.
Implied claims count too. A before-and-after photo implies typical results, and leaving out key facts can deceive as surely as a false statement.
- When evidence is preliminary, say so plainly, in the ad itself, in a clear and conspicuous disclosure.
- Disclose material connections, such as free services or payment, right next to the endorsement.
- You are legally responsible for what your endorsers and affiliates claim on your behalf, per the FTC’s health products guidance.
- The FTC has also proposed a rule on fake reviews, so clean up your review practices now.
Pro Tip: Save the study citation for each claim in the ad’s creative folder. If you can’t find the support in thirty seconds, the claim isn’t ready.
How do you avoid FDA trouble with compounded drug promotion?
Compounded drugs are not FDA-approved. Presenting them as equivalent to an approved brand drug is misbranding, and that is exactly what regulators have gone after. The FDA warned 30 telehealth companies over illegal marketing of compounded GLP-1s, citing false equivalence claims and pharmacies mislabeled as “FDA-approved.” Individual letters, like the one to Altru Telehealth, spell out what crossed the line with compounded semaglutide and tirzepatide.
- Strip out “same as,” “generic version of,” and any brand-name comparison.
- Never suggest the compounder is FDA-approved or FDA-licensed.
- Don’t imply your telehealth brand is the compounder when it isn’t.
- Send every drug-related line to regulatory counsel before launch.
If you advertise compounding services, our compliance-first playbook for compounding pharmacy marketing goes deeper.
How do you handle testimonials, reviews, and patient consent?
Patient stories sell, and they also create risk. The FTC Endorsement Guides emphasize disclosing material connections near the endorsement. The proposed review rule targets fake reviews, review hijacking, and undisclosed insider reviews, so staff and family reviews need labels too.
A testimonial that identifies a patient may involve health information. Check applicable privacy requirements and obtain consent when required before using health information in marketing.
- Get signed, specific authorization naming where the story will run.
- Record any compensation or perk given to the patient.
- Store the consent form with the creative asset.
- Note an expiration or withdrawal process.
- Re-check consent before reusing the story on a new channel.
Our post on patient engagement and compliance marketing covers consent in patient communications.
Where can you advertise versus where can you treat?
Advertising reach and treatment authority are separate things. Licensure follows the patient’s location, and HHS licensure guidance says to verify state-specific permitting before you offer or market services in that state.
Lawful pathways exist, but rules vary state by state:
- A full license in the patient’s state.
- A licensure compact, where the state participates.
- Telehealth registration, which typically asks for a valid license elsewhere, malpractice coverage, and a clean disciplinary record, per HHS licensing resources.
- Temporary practice provisions, where available.
Fix targeting at the source: limit geotargets to states where you can treat, build state-specific landing pages that name where each clinician is licensed, and exclude everywhere else.
Pro Tip: Pull your credentialing roster and your ad geotargets side by side every quarter. Mismatches show up fast.
What privacy and HIPAA rules touch your ads?
HHS privacy guidance confirms HIPAA reaches telehealth communications and data storage. Many states add digital health privacy laws that regulate third-party vendors and data commercialization. If an ad activity uses health information, you may need patient authorization, and any vendor handling that data needs a BAA.
- Keep PHI out of creative, URLs, and form-fill parameters.
- Confirm a BAA exists before any tracking or automation tool goes live.
- Handle only the minimum data a campaign needs.
- Map where data flows for each campaign, from click to CRM.
Two of our posts help here: HIPAA-compliant call tracking and HIPAA-compliant marketing automation.
Why do Google Ads and LegitScript block telehealth campaigns?
Google’s healthcare policy restricts promotion of online prescribing and prescription drug sales. Telemedicine advertisers who facilitate prescribing may need FDA-cleared microneedling before ads run.
Landing pages get disapproved for a few repeat reasons:
- Drug-sale language, or claims of direct drug access.
- An unclear clinical process, with no mention of a clinician visit.
- Missing verification or certification details.
Before you submit, gather your license records, business documents, and clinical workflow description, then scrub the page of anything that reads like a drug storefront. Social platforms add their own rules, so check each one, starting with our Facebook ad policy guide.
How do you launch a compliant campaign, step by step?
- Claim audit: link every health claim to documentation in a claims file.
- Drug language audit: remove equivalence statements and fix compounder phrasing.
- Testimonial check: confirm consent, document material connections, place disclosures.
- Licensing and targeting: confirm licensure for each targeted state, then restrict targeting to match.
- Privacy and vendors: verify BAAs, keep PHI out of creative, map data flows.
- Platform prep: collect Google and LegitScript documents and pre-check landing pages.
- Monitoring: watch live ads, set a fast response workflow, and name a legal contact for enforcement notices.
Pro Tip: Assign one owner to the claims file. When everyone owns it, nobody updates it.
Why compliance is a growth strategy, not a tax
Telehealth teams tend to treat compliance as the thing that slows launches. I see it the other way. The enforcement wave of 2025 and 2026 hit companies that cut corners, and a suspended ad account or a warning letter can make compliance oversights costly. Patients trust providers who are straight with them, and trust compounds.
— Opinly
How can KLYR Media help your telehealth marketing stay compliant?
Most telehealth teams know the rules and still get stuck on implementation. We build HIPAA-compliant web design for landing pages that carry the right disclosures, run healthcare PPC with platform verification prepped from day one, and set up retention automation. Ask us for an audit of your current ads and landing pages.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
What are the updated telehealth guidelines for 2026?
There is no single new rulebook. Current expectations combine FTC substantiation and endorsement rules, FDA enforcement against misleading compounded drug marketing, and state-by-state licensure. Check the FTC, FDA, and HHS pages in the Sources section for the latest.
What are the four main types of advertising regulation in the United States?
A practical way to sort them: federal agency rules like the FTC’s, FDA drug-promotion limits, state law, and platform policies. Telehealth ads usually face all four at once, so review each layer.
What is an example of telemedicine?
A video visit where a licensed clinician evaluates a patient in another location is the classic example. Remote monitoring and asynchronous messaging count as well. Whatever the format, licensure follows the patient’s state.
Where is pharmaceutical advertising legal?
Rules differ by country and by state, and prescription drug ads face tight limits in many places. In the U.S., the FDA regulates drug promotion, and platforms like Google add their own prescription advertising limits. Ask regulatory counsel about your specific products.
Sources
- Ftc
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s | FDA
- Telehealth
- Healthcare and medicines
